Corcept Therapeutics (NASDAQ: CORT) reported Q1 EPS of ($0.06), $0.09 worse than the analyst estimate of $0.03. Revenue for the quarter came in at $27.6 million versus the consensus estimate of $25.53 million.

GUIDANCE:

Corcept Therapeutics sees FY2017 revenue of $125-135 million, versus the consensus of $124 million.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.